163 related articles for article (PubMed ID: 32514196)
1. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
[TBL] [Abstract][Full Text] [Related]
2. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
4. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
[TBL] [Abstract][Full Text] [Related]
5. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
[TBL] [Abstract][Full Text] [Related]
6. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
8. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
9. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
[TBL] [Abstract][Full Text] [Related]
12. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
13. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
Masuku SD; Berhanu R; Van Rensburg C; Ndjeka N; Rosen S; Long L; Evans D; Nichols BE
Int J Tuberc Lung Dis; 2020 Apr; 24(4):376-382. PubMed ID: 32317060
[TBL] [Abstract][Full Text] [Related]
14. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?
Pooran A; Pieterson E; Davids M; Theron G; Dheda K
PLoS One; 2013; 8(1):e54587. PubMed ID: 23349933
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
16. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
[TBL] [Abstract][Full Text] [Related]
17. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial.
Rosu L; Madan J; Worrall E; Tomeny E; Squire B;
BMJ Open; 2020 Dec; 10(12):e042390. PubMed ID: 33371043
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
Wolfson LJ; Walker A; Hettle R; Lu X; Kambili C; Murungi A; Knerer G
PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
[TBL] [Abstract][Full Text] [Related]
20. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.
Sinanovic E; Ramma L; Vassall A; Azevedo V; Wilkinson L; Ndjeka N; McCarthy K; Churchyard G; Cox H
Int J Tuberc Lung Dis; 2015 Feb; 19(2):172-8. PubMed ID: 25574915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
